Literature DB >> 29714589

Strengthening Health Products Regulatory Systems to Enhance Access to Quality Health Products in the Asia-Pacific.

John C W Lim1.   

Abstract

Asia-Pacific is a region of fast growing opportunity for biomedical research and marketing of new health products by pharmaceutical and medical device companies. While national regulatory authorities have the responsibility to ensure timely access to innovative, effective, and safe therapies, many face capacity and resource constraints that limit their ability to guarantee a robust regulatory system capable of licensing and monitoring novel medicines and medical devices, and tackling substandard and falsified products. The region's regulatory landscape is also fragmented with country-specific requirements that create barriers to entry for new health products. To help address these challenges, the Duke-National University of Singapore's (Duke-NUS) Centre of Regulatory Excellence (CoRE) was established in 2014 with the strategic goals to strengthen the region's regulatory agencies through capacity development, regulatory convergence, work sharing, and nurturing networks for leadership and systems innovation. A smart and mature regulatory system in Asia-Pacific is pivotal to promote biomedical innovation and enhance equitable, sustainable access of populations to quality health products that are safe and efficacious.

Keywords:  Asia-Pacific; regulatory convergence; regulatory excellence; regulatory innovation; regulatory systems strengthening

Mesh:

Substances:

Year:  2018        PMID: 29714589     DOI: 10.1177/2168479018769285

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  2 in total

1.  An Evaluation of Malaysian Regulatory Process for New Active Substances Approved in 2017 Using the OpERA Methodology.

Authors:  Noraisyah Mohd Sani; Neil McAuslane; Siti Hidayah Kasbon; Rosilawati Ahmad; Faridah Aryani Md Yusof; Prisha Patel
Journal:  Ther Innov Regul Sci       Date:  2020-03-28       Impact factor: 1.778

2.  A Baseline Analysis of Regulatory Review Timelines for ANVISA: 2013-2016.

Authors:  Prisha Patel; Daniela Marreco Cerqueira; Gustavo Mendes Lima Santos; Renata de Lima Soares; Varley Dias Sousa; Lawrence Liberti; Neil McAuslane
Journal:  Ther Innov Regul Sci       Date:  2020-06-09       Impact factor: 1.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.